Guangxi Innovate Pharmaceutical

Guangxi Innovate Pharmaceutical is a China-based pharmaceutical company in Liuzhou, Guangxi that appears to operate in veterinary medicine. Publicly available evidence links the company to development of anemoside B4 (AB4) for canine pneumonia, including a prospective randomized controlled study published in 2025 and a pharmacokinetic/safety study in healthy dogs. The company therefore appears to be a small, privately held veterinary-focused drug developer rather than a broad human biopharma company. Beyond AB4, little reliable public information is available on a broader pipeline, partnerships, financing history, or corporate footprint. The company may also have formulation and manufacturing capabilities for investigational veterinary injections, but this is not well documented in easily accessible English-language sources.